Thoma Bravo Announces Strategic Growth Investment in Bluesight to Support the Company’s Acquisition of Medacist


Thoma Bravo, a leading software investment firm, today announced the closing of a strategic growth investment in Bluesight, the Medication Intelligence™ Company. The investment is expected to further enhance Bluesight’s drug diversion prevention offerings through its acquisition of Medacist, a pioneer in drug diversion monitoring, and continue to grow Bluesight’s inventory management and spend optimization offerings.